A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension
NCT ID: NCT05523323
Last Updated: 2025-04-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
112 participants
INTERVENTIONAL
2020-10-30
2025-03-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypotheses include:
* Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).
* Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Progression Free Survival (PFS) per RECIST 1.1 as assessed by BICR.
* Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to overall survival (OS).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study
NCT04889118
Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China
NCT04740996
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study
NCT04716933
Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China
NCT04857164
4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC
NCT05980702
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pembrolizumab + Lenvatinib
Participants receive lenvatinib 20 mg orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib will be administered until progressive disease or unacceptable toxicity.
Lenvatinib
Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD
Pembrolizumab
Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles
Pembrolizumab + Placebo
Participants receive lenvatinib-matching placebo orally once a day (QD) plus pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W). Pembrolizumab will be administered for up to 35 cycles (approximately 24 months). Lenvatinib-matching placebo will be administered until progressive disease or unacceptable toxicity.
Pembrolizumab
Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles
Placebo
Lenvatinib-matching placebo, oral capsules, administered once daily (QD)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lenvatinib
Lenvatinib, 20 mg (two 10-mg oral capsules) administered QD
Pembrolizumab
Pembrolizumab (MK-3475), 200 mg, every 3 weeks (Q3W) by intravenous (IV) infusion for up to 35 3-week cycles
Placebo
Lenvatinib-matching placebo, oral capsules, administered once daily (QD)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has a primary tumor location of oropharynx, oral cavity, hypopharynx, or larynx Note: Primary tumor site of nasopharynx (any histology) or unknown primary tumor (including p16+ unknown primary) are not eligible
Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. If the contraception requirements in the local label for any of the study interventions is more stringent than the requirements above, the local label requirements are to be followed
* Male participants agree to use approved contraception during the treatment period for at least 7 days after the last dose of lenvatinib/placebo, or refrain from heterosexual intercourse during this period
* Female participants are not pregnant or breastfeeding, and are not a woman of childbearing potential (WOCBP), OR are a WOCBP that agrees to use contraception during the treatment period (or 14 days prior to the initiation of study treatment for oral contraception) and for at least 120 days post pembrolizumab, or 30 days post lenvatinib/placebo, whichever occurs last
* Has measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) Note: Lesions situated in a previously irradiated area are considered measurable if progression has been showed in such lesions
* Participants with oropharyngeal cancer must have results from testing of human papillomavirus (HPV) status
* Has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 1
* Has adequately controlled blood pressure with or without antihypertensive medications
* Has adequate organ function
Exclusion Criteria
* Has radiographic evidence of major blood vessel invasion/infiltration or tumor demonstrates \>90 degree abutment or encasement of a major blood vessel Note: The degree of proximity to major blood vessels should be considered because of the potential risk of severe hemorrhage associated with tumor shrinkage/necrosis after lenvatinib therapy
* Has a history of re-irradiation to any head and neck sites of disease including the cervical, infraclavicular or supraclavicular lymph nodes for head and neck cancer
* Has ulceration and/or fungation of disease onto the skin surface
* Has a history of any contraindication or has a severe hypersensitivity to any components of pembrolizumab (≥Grade 3) or lenvatinib
* Has pre-existing ≥Grade 3 gastrointestinal or non-gastrointestinal fistula
* Has a history of a gastrointestinal condition or procedure that, in the opinion of the investigator, may affect oral study drug absorption
* Has clinically significant cardiovascular impairment within 12 months of the first dose of study intervention, such as history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, myocardial infarction or cerebrovascular accident/transient ischemic attack (TIA)/stroke, cardiac revascularization, or cardiac arrhythmia associated with hemodynamic instability
* Has disease that is suitable for local therapy administered with curative intent
* Had PD within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC
* Has had major surgery within 3 weeks before to first dose of study interventions
* Has difficulty swallowing capsules or ingesting a suspension orally or by a feeding tube
* Has received prior therapy with lenvatinib or pembrolizumab
* Received last dose of systemic therapy for locoregionally advanced disease less than 6 months before signing consent
* Has received prior therapy with an anti-programmed cell death 1 protein (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti-programmed cell death ligand 2 (anti PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137)
* Has received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization
* Has received prior radiotherapy within 2 weeks of start of study intervention
* Has received a live vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed
* Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention-administration
* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention
* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded
* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
* Has an active autoimmune disease that has required systemic treatment in past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid) is allowed
* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
* Has an active infection requiring systemic therapy. (e.g., tuberculosis, known viral or bacterial infections, etc.)
* Has a known history of human immunodeficiency virus (HIV) infection
* Has a known history of hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive) or known active hepatitis C virus (defined as HCV ribonucleic acid (RNA) \[qualitative\] is detected) infection
* Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study intervention
* Has had an allogenic tissue/solid organ transplant
* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Inc.
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Merck Sharp & Dohme LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anhui Cancer Hospital-Radiology Department ( Site 3333)
Hefei, Anhui, China
Beijing Tongren Hospital affiliated to Capital Medical University ( Site 3343)
Beijing, Beijing Municipality, China
Beijing Cancer Hospital ( Site 3314)
Beining, Beijing Municipality, China
Peking Union Medical College Hospital ( Site 3304)
Bejiing, Beijing Municipality, China
Chongqing Cancer Hospital ( Site 3327)
Chongqing, Chongqing Municipality, China
Fujian Provincial Cancer Hospital ( Site 3326)
Fuzhou, Fujian, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 3336)
Guangzhou, Guangdong, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 3338)
Guangzhou, Guangdong, China
The First Affiliated Hospital, Sun Yat-sen University ( Site 3344)
Guangzhou, Guangdong, China
Guangxi Medical University Affiliated Tumor Hospital ( Site 3322)
Nanning, Guangxi, China
Guizhou Cancer Hospital ( Site 3330)
Guiyang, Guizhou, China
The Third Affiliated Hospital of Harbin Medical University ( Site 3302)
Harbin, Heilongjiang, China
Henan Cancer Hospital ( Site 3309)
Zhengzhou, Henan, China
Wuhan Union hospital Cancer Center ( Site 3307)
Wuhan, Hubei, China
Tongji Hospital Tongji Medical,Science & Technology ( Site 3316)
Wuhan, Hubei, China
Hunan Cancer Hospital ( Site 3311)
Changsha, Hunan, China
Xiangya Hospital of Central South University ( Site 3305)
Changsha, Hunan, China
Hunan Cancer Hospital ( Site 3334)
Changsha, Hunan, China
Changzhou Tumor Hospital - Changzhou Fourth People's Hospital ( Site 3339)
Changzhou, Jiangsu, China
Jiangxi Cancer Hospital ( Site 3313)
Nanchang, Jiangxi, China
Jilin Cancer Hospital ( Site 3310)
Changchun, Jilin, China
The First Affiliated Hospital of Xi an Jiaotong University ( Site 3328)
Xi'an, Shaanxi, China
Shanghai 9th People hospital ( Site 3332)
Shanghai, Shanghai Municipality, China
Fudan University Shanghai Cancer Center ( Site 3324)
Shanghai, Shanghai Municipality, China
Shanghai East Hospital ( Site 3300)
Shanghai, Shanghai Municipality, China
West China Hospital of Sichuan University ( Site 3308)
Chengdu, Sichuan, China
Tianjin Medical University Cancer Hospital ( Site 3312)
Tianjin, Tianjin Municipality, China
Zhejiang Cancer Hospital ( Site 3303)
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Merck Clinical Trials Information
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-7902-010 China Extension
Identifier Type: OTHER
Identifier Source: secondary_id
205240
Identifier Type: REGISTRY
Identifier Source: secondary_id
LEAP-10
Identifier Type: OTHER
Identifier Source: secondary_id
7902-010 China Extension
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.